Understand the source comparison
Best Peptides for Telehealth Clinicians: Feature Comparison
Semaglutide Weekly Weight reduction, A1C Stable 14 days at 25°C Low. Single weekly injection Highest telehealth success rate; predictable side effects, algorithmic titration Tirzepatide Superior efficacy vs semaglutide; same remote manageability BPC-157 Daily
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide
- Weekly
- Weight reduction, A1C
- Stable 14 days at 25°C
- Low. Single weekly injection
- Highest telehealth success rate; predictable side effects, algorithmic titration
- Tirzepatide
- Superior efficacy vs semaglutide; same remote manageability
- BPC-157
- Daily
- Pain reduction, mobility
- Stable 7 days at 25°C post-reconstitution
- Moderate. Reconstitution errors common
- Works if patients follow instructional video; fails without it
- Thymosin Beta-4
- Tissue repair markers
- Effective for musculoskeletal complaints; requires patient-reported outcome tracking
- Melanotan II
- Skin pigmentation
- High. Dose-dependent severe side effects
- Not recommended for telehealth; side effect profile too unpredictable
- Ipamorelin / CJC-1295
- Daily (timing-sensitive)
- IGF-1 elevation
- High. Timing errors negate efficacy
- Requires lab monitoring and precise adherence; poor fit for remote care